Bremelanotide PT-141 was developed from the peptide hormone Melanotan II for aphrodisiac effects. Bremelanotide PT-141 effects sexual function via interaction with the hypothalamus. Its usage has been found to induce the rapid onset of arousal. This peptide has been found to increase erection in 80% of males who did not respond to Viagra or Cialis. Bremelanotide PT-141 has all shown an ability to increase the chances of women achieving at least one sexually gratifying experience by up to 50%.
Unlike other sexual-enhancement drugs, Bremelanotide PT-141 acts at the level of the brain, thus eliciting a rather natural sexual response. Melanotan II (MT II) is a peptide hormone that acts to increase sexual arousal by interacting with the hypothalamus in the brain. As a derivative of MT II, Bremelanotide PT-141 induces sexual arousal by binding to melanocortin receptors in the hypothalamus.
Bremelanotide PT-141 is available for subcutaneous injection.
Reported side effects of Bremelanotide PT-141 are flushing, nausea and gastrointestinal upset. No contraindications have been reported.
Bremelanotide PT-141 has been shown to:
Bremelanotide PT-141 was developed from the peptide hormone Melanotan II for its aphrodisiac properties. Unlike other sexual-enhancement drugs that act via the vascular system, Bremelanotide PT-141 stimulates sexual desire by acting directly upon the nervous system.
Bremelanotide PT-141 improves female sexual dysfunction, induces erections in men, and heightens libido. Clinical studies indicate that Bremelanotide PT-141 has been shown to be 80% effective in men who do not respond to Viagra or Cialis and causes a 50% increase in sexually satisfying experiences in women.
Inject 0.2mL subcutaneously as needed, 30 minutes to 6 hours prior to sexual activity. The initial dose, or loading dose, will establish a time frame for response. Men should start at 0.1ml and titrate up to and not exceeding 0.4ml. Women should start at 0.2ml dosing protocol.
Reported side effects of Bremelanotide PT-141 include flushing, nausea, and gastrointestinal upset. No contraindications have been reported. Some doctors have recommended pairing Bremelanotide PT-141 with an antacid or an antihistamine to help combat side effects.
Yes, Bremelanotide PT-141 (or other peptides) are safe to use even though they may not have FDA approval status. All compounded drugs are non-FDA approved as they differ from the FDA approved manufactured product in some sense. Compounding pharmacies are governed and regulated by the FDA and every state board of pharmacy in which they are licensed. Compounded medications must be compounded in a licensed pharmacy, made up of chemicals that are sourced from an FDA registered manufacturing facility, and follow all United States Pharmacopeia (USP) guidelines.
All medications are compounded in house at Tailor Made Compounding in the United States. Tailor Made Compounding is a 503A compounding pharmacy outfitted with two USP 795 Non-Sterile compounding facilities, three USP 797 Sterile compounding facilities, and one USP 800 Hazardous Sterile compounding facility.
It is not recommended that this product be taken by those who are pregnant or nursing without consulting with a medical professional first.
Bremelanotide PT-141 has been shown to exhibit aphrodisiac properties and induce sexual arousal in both men and women.
Bremelanotide PT-141 does not exhibit any chemical properties that would require any kind of food or dietary restrictions while taking.
All chemicals and components used must come from an FDA Registered manufacturing facility with a certificate of analysis to authenticate the identity and purity of each chemical. All products are compounded in correspondence with USP 797 guidelines. Each solution is sterilized using a 0.22um sterile syringe filter within an ISO 5 (sterile) environment. A sample from each batch is sent out to a third-party analytical laboratory for USP 71, endotoxin, and USP 81 testing and must indicate passing results before the batch is released for dispensing.
Reconstituted Bremelanotide PT-141 should be stored under refrigerated conditions. However, stability data does indicate that it is stable outside of refrigerated conditions for up to 7 days without compromising the stability of the medicine.
As a 503A pharmacy, we require patient specific prescriptions for all items. As a prescribed medication each product is safe to travel with and should not be seized. All products are stable for up to 7 days outside of refrigeration but should be limited if possible during travel. Stability data also indicates that this medication is not damaged or compromised when exposed to x-rays during standard security checks.
It is recommended to consult a medical professional prior to the first injection to learn proper techniques via demonstration. Most of the medications are administered via subcutaneous injection with a short needle inserted into the fatty tissue layer between the skin and the muscle.
‡ These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.